Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice

References

• European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398. doi: 10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099–2108. doi: 10.1002/hep.27406
   PubMed Web of Science ®Google Scholar
• Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut. 2012;61:333–336. doi: 10.1136/gutjnl-2011-300937
   PubMed Web of Science ®Google Scholar
• Lok AS, et al. Hepatitis B virus drug resistance working group. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254–265. doi: 10.1002/hep.21698
   PubMed Web of Science ®Google Scholar
• Baldick CJ, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol. 2008;48:895–902. doi: 10.1016/j.jhep.2007.12.024
   PubMed Web of Science ®Google Scholar
• Tenney DJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–1514. doi: 10.1002/hep.22841
   PubMed Web of Science ®Google Scholar
• Hayashi S, et al. Characterization of novel entecavir resistance mutations. J Hepatol. 2015;63:546–553. doi: 10.1016/j.jhep.2015.03.020
   PubMed Web of Science ®Google Scholar
• Ahn SL, et al. Substitution at rt269 in hepatitis B virus polymerase is a compensatory mutation associated with multi-drug resistance. Plos One. 2015;10:e0136728. doi: 10.1371/journal.pone.0136728
   PubMed Web of Science ®Google Scholar
• Shirvani-Dastgerdi E, et al. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol. 2017;67:246–254. doi: 10.1016/j.jhep.2017.03.027
   PubMed Web of Science ®Google Scholar
• Ji D, et al. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. J Clin Virol. 2012;54:66–72. doi: 10.1016/j.jcv.2012.02.003
   PubMed Web of Science ®Google Scholar
• Liu Y, et al. rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus. Plos One. 2014;9:e89015. doi: 10.1371/journal.pone.0089015
   PubMed Web of Science ®Google Scholar
• Liu Y, et al. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients. Antivir Ther. 2014;19:551–558. doi: 10.3851/IMP2775
   PubMed Web of Science ®Google Scholar
• Liu Y, et al. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. J Viral Hepat. 2015;22:328–334. doi: 10.1111/jvh.12298
   PubMed Web of Science ®Google Scholar
• Liu Y, et al. Increased occurrence of mutant rtI233V of HBV in patients with adefovir therapy. Antivir Ther. 2016;21:9–16. doi: 10.3851/IMP2971
   PubMed Web of Science ®Google Scholar
• Liu Y, et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat. 2011;18:e29–e39. doi: 10.1111/j.1365-2893.2010.01360.x
   PubMed Web of Science ®Google Scholar
• Liu Y, et al. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther. 2010;15:1185–1190. doi: 10.3851/IMP1679
   PubMed Web of Science ®Google Scholar
• Rajoriya N, Combet C, Zoulim F, et al. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281–1297. doi: 10.1016/j.jhep.2017.07.011
   PubMed Web of Science ®Google Scholar
• Xue Y, et al. Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant. Emerg Microbes Infect. 2017;6:e15. doi: 10.1038/emi.2017.2
   PubMed Web of Science ®Google Scholar
• Tong S, Li J, Wands JR, et al. Hepatitis B virus genetic variants: biological properties and clinical implications. Emerg Microbes Infect. 2013;2:e10. doi: 10.1038/emi.2013.10
   PubMed Web of Science ®Google Scholar
• Yang H, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 2002;36:464–473. doi: 10.1053/jhep.2002.34740
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. doi: 10.1002/hep.23190
   PubMed Web of Science ®Google Scholar
• Svarovskaia ES, et al. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovirbased regimen. J Viral Hepat. 2013;20:131–140. doi: 10.1111/j.1365-2893.2012.01638.x
   PubMed Web of Science ®Google Scholar
• Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593–1608. doi: 10.1053/j.gastro.2009.08.063
   PubMed Web of Science ®Google Scholar
• Baldick CJ, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology. 2008;47:1473–1482. doi: 10.1002/hep.22211
   PubMed Web of Science ®Google Scholar
• Walsh AW, Langley DR, Colonno RJ, et al. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. Plos One. 2010;5:e9195. doi: 10.1371/journal.pone.0009195
   PubMed Web of Science ®Google Scholar
• Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2:147–151. doi: 10.1007/s12072-008-9048-3
   PubMed Web of Science ®Google Scholar
• Zhao L, et al. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation. Antiviral Res. 2018;154:26–34. doi: 10.1016/j.antiviral.2018.04.003
   PubMed Web of Science ®Google Scholar
• Mirandola S, et al. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. Antiviral Res. 2012;96:422–429. doi: 10.1016/j.antiviral.2012.09.014
   PubMed Web of Science ®Google Scholar
• Li XD, et al. Comparison of detection rate and mutational pattern of drug-resistant mutations between a large cohort of genotype B and genotype C hepatitis B virus-infected patients in North China. Microb Drug Resist. 2017;23:516–522. doi: 10.1089/mdr.2016.0093
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology and Chinese Society of Infectious Diseases & Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010Version). Zhonghua Gan Zang Bing Za Zhi (Chinese J Hepatol). 2011;19:13–24.
   PubMedGoogle Scholar
• Hou JL, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 Update). J Clin Transl Hepatol. 2017;5:297–318. doi: 10.14218/JCTH.2016.00019
   PubMed Web of Science ®Google Scholar
• Murakami E, et al. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. J Infect. 2016;72:91–102. doi: 10.1016/j.jinf.2015.09.038
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases & Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl). 2007;120:2159–2173. doi: 10.1097/00029330-200712020-00002
   PubMed Web of Science ®Google Scholar
• Liao H, et al. Characterization of hepatitis B virus (HBV) preS/S gene mutations in blood donors with occult HBV infection in the Baoji area of North China. Transfusion. 2017;57:857–866. doi: 10.1111/trf.14046
   PubMed Web of Science ®Google Scholar
• Durante D, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology. 2004;40:855–864. doi: 10.1002/hep.20388
   PubMed Web of Science ®Google Scholar
• Villet S, Pichoud C, Villeneuve JP, et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131:1253–1261. doi: 10.1053/j.gastro.2006.08.013
   PubMed Web of Science ®Google Scholar
• Lu YP, et al. Replication of clinical hepatitis B virus isolate and its application for selecting antiviral agents for chronic hepatitis B patients. World J Gastroenterol. 2008;14:3490–3496. doi: 10.3748/wjg.14.3490
   PubMed Web of Science ®Google Scholar
• Phillips JC, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2010;26:1781–1802. doi: 10.1002/jcc.20289
   Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33–38. doi: 10.1016/0263-7855(96)00018-5
   PubMed Web of Science ®Google Scholar